Audentes Therapeutics, Inc. (BOLD)


Stock Price Forecast

Jan. 14, 2020


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Audentes Therapeutics, Inc. chart...

About the Company

Audentes Therapeutics, Inc. is a biotechnology company, which engages on development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. Its products include AT001 for the treatment of X-Linked Myotubular Myopathy, AT002 for the treatment of Pompe disease, and AT003 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA.

Sector

Health Technology

Industry

Biotechnology

Employees

207

CEO

Natalie C. Holles

Exchange

NASDAQ

Website

http://audentestx.com

$M

Total Revenue

207

Employees

$3B

Market Capitalization

-15.11

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $BOLD News

Astellas buys gene therapy company for $3bn

4y ago, source: pharmaphorum

Astellas has announced it will be acquiring gene therapy specialists Audentes Therapeutics for a total equity value of approximately $3 billion, adding a new focus area to its drug discovery efforts.

Astellas agrees to buy Audentes in US$3b gene-therapy deal

4y ago, source: The Star

TOKYO: Astellas Pharma Inc. agreed to buy Audentes Therapeutics Inc. for about $3 billion, the latest deal by a pharmaceutical company eager to push into promising gene-therapy technologies.

Ovid Therapeutics Inc OVID

11h ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Versant Venture Capital IV, L.P.'s Net Worth

4d ago, source: Benzinga.com

Inc., Tempest Therapeutics, Inc., Audentes Therapeutics, Inc., and CRISPR Therapeutics AG. Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro!

EFTR eFFECTOR Therapeutics, Inc.

4d ago, source: Seeking Alpha

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product ...

Louis G Lange's Net Worth

18d ago, source: Benzinga.com

Who is Louis G Lange? Louis G Lange has an estimated net worth of $30 Million. This is based on reported shares across multiple companies, which include GILEAD SCIENCES INC, Epiphany Technology ...

Kintara Therapeutics Inc KTRA

16h ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript

19d ago, source: Yahoo Finance

G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript February 28, 2024 G1 Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.21, expectations were $-0.27.

Entrada Therapeutics: Buy Rating on Strong Financials and Promising Clinical Pipeline

1d ago, source: Business Insider

Ram Selvaraju has given his Buy rating due to a combination of factors related to Entrada Therapeutics Inc’s solid financial position and promising clinical developments. Entrada concluded the fiscal ...

Intellia Therapeutics, Inc.

2mon ago, source: CNN

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Analysts Are Cutting Their Estimates: Here's What You Need To Know

23d ago, source: Yahoo Finance

Intellia Therapeutics, Inc. (NASDAQ:NTLA) shareholders are probably feeling a little disappointed, since its shares fell 5.9% to US$26.10 in the week after its latest full-year results.

KROS Keros Therapeutics, Inc.

5d ago, source: Seeking Alpha

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...